Breaking Finance News

Zacks Investment Research downgraded Juno Therapeutics Inc (NASDAQ:JUNO) to Sell in a report released today.

Yesterday Juno Therapeutics Inc (NASDAQ:JUNO) traded 1.58% higher at $29.56. The company’s 50-day moving average is $30.66 and its 200-day moving average is $36.29. The last closing price is down -18.30% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 1,071,309 shares of the stock traded hands, down from an average trading volume of 2,248,740

Zacks Investment Research has downgraded Juno Therapeutics Inc (NASDAQ:JUNO) to Sell in a report released on 10/5/2016.

See Chart Below

Juno Therapeutics Inc (NASDAQ:JUNO)

Juno Therapeutics Inc has a 52 week low of $22.37 and a 52 week high of $57.82 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 11 brokers have issued a research note on the company. The average stock price target is $55.73 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Juno Therapeutics Inc (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno's product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company's CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.